{
    "clinical_study": {
        "@rank": "153095", 
        "arm_group": {
            "arm_group_label": "Normal human controls", 
            "description": "Observational study. Subjects are screened for the absence of severe illnesses and followed prospectively with sequential blood draws, noting the occurence of acute and chronic severe illnesses.\nSubjects are matched by age groups and sex with patients of the prospective cohort EUPA including patients with recent-onset inflammatory polyarthritis."
        }, 
        "biospec_descr": {
            "textblock": "Genomic DNA extracted from peripheral blood"
        }, 
        "biospec_retention": "Samples With DNA", 
        "brief_summary": {
            "textblock": "We have established a cohort of patients with recent-onset inflammatory arthritis called\n      EUPA. This cohort was established to define novel biomarkers of poor outcomes. We want to\n      study telomere length and TREC numbers in peripheral blood as new biomarkers.\n\n      This cohort of normal controls was established to be able to define the stability over short\n      periods of time of telomere length and TREC numbers in normal individuals, in order to\n      compare with arthritis patients."
        }, 
        "brief_title": "Length of Telomeres and Number of TRECs From Peripheral Blood in Normal Subjects Over Time", 
        "completion_date": {
            "#text": "April 2020", 
            "@type": "Anticipated"
        }, 
        "condition": "Normal Human Controls", 
        "detailed_description": {
            "textblock": "It is difficult to establish early on the prognosis of patients with recent-onset\n      polyarthritis. We want to know if we can use the length of telomeres in periphjeral blood\n      cells at baseline as a novel prognostic marker.\n\n      In order to be able to interpret our observations in arthritis patients over time, we need\n      to compare these results with those observed in normal human controls adjusted for gender\n      and for age groups.\n\n      These patients are first screened for the presence of acute or chronic severe diseases\n      (cancer, cardiovascular, articular, et...). They then have genomic DNA extracted from\n      peripheral blood and seen at 3 months interval for a year than annually. At each blood draw,\n      the appearance of acute or chronic diseases is noted."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        Absence of acute infectious, traumatic or immunologic disease Absence of severe chronic\n        diseases Age and sex concordant with the stratification of patients from a longitudinal\n        cohort of early inflammatory arthritis (EUPA)\n\n        Exclusion Criteria:\n\n        History of cancer (except a single episode of non-melanocytic skin cancer) Severe\n        cardiovascular disease(i.e. difficult to control or requiring multiple drugs) Chronic\n        infection Inflammatory arthritis Severe high blood pressure or diabetes (i.e. difficult to\n        control or requiring multiple drugs) Any severe disease affecting function or difficult to\n        control or requiring multiple drugs"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "85 Years", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Normal human controls apparied for gender and for groups of age with patients of the EUPA\n        cohort (with inflammatory arthritis of between 1 and 12 months duration presenting for\n        clinical care at the Rheumatology Division of the Centre hospitalier universitaire de\n        Sherbrooke.)"
            }
        }, 
        "enrollment": {
            "#text": "200", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 30, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01982890", 
            "org_study_id": "Telomeres and TREC"
        }, 
        "intervention": {
            "arm_group_label": "Normal human controls", 
            "description": "No intervention as this group is simply followed prospectively.", 
            "intervention_name": "Control", 
            "intervention_type": "Other"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Telomere length", 
            "Longitudinal observation"
        ], 
        "lastchanged_date": "November 6, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Sherbrooke", 
                    "country": "Canada", 
                    "state": "Quebec", 
                    "zip": "J1H 5N4"
                }, 
                "name": "Centre hospitalier universitaire de Sherbrooke"
            }
        }, 
        "location_countries": {
            "country": "Canada"
        }, 
        "number_of_groups": "1", 
        "official_title": "Telomere Shortening as a Prognostic Marker in Early Inflammatory Arthritis: Establishing the Stability of Telomeres in Normal Individuals", 
        "overall_official": {
            "affiliation": "Centre Hospitalier Universitaire de Sherbrooke", 
            "last_name": "Gilles Boire, MD, MSc", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Enrolling by invitation", 
        "oversight_info": {
            "authority": "Canada: Ethics Review Committee", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "April 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Blood draws to collect genomic DNA both from total peripheral blood cells and from peripheral blood mononucleaer cells are done at 0, 3, 6, 9 and 12 months (along with a complete blood count). At each time, patients are assessed for severe acute and chronic diseases", 
            "measure": "Estimation of variability of multiple measures of the length of telomeres over one year", 
            "safety_issue": "No", 
            "time_frame": "Over one year"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01982890"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Universit\u00e9 de Sherbrooke", 
            "investigator_full_name": "Gilles Boire", 
            "investigator_title": "Doctor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "Blood draws at these time points. T cell Excision Circles are measured from genomic DNA at the same time as is telomere length", 
                "measure": "TREC numbers in peripheral blood over time", 
                "safety_issue": "No", 
                "time_frame": "At 3, 6, 9, 12, 18, 24, 36, 48 and 60 months"
            }, 
            {
                "description": "From the end of the first year, patients will be followed yearly with an assessment of the occurence of new severe acute and chronic diseases and a blood draw to collect genomic DNA isolated from total blood cells and from isolated blood mononuclear cells, along with a complete blood count to assess lymphocyte numbers.", 
                "measure": "Estimation of the variability of the measure of length of telomeres with multiple measures over 5 years", 
                "safety_issue": "No", 
                "time_frame": "5 years"
            }
        ], 
        "source": "Universit\u00e9 de Sherbrooke", 
        "sponsors": {
            "collaborator": {
                "agency": "Janssen, LP", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Universit\u00e9 de Sherbrooke", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2005", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational [Patient Registry]", 
        "target_duration": "5 Years", 
        "verification_date": "November 2013"
    }
}